Press Releases

    • SEP 10 2018

    NCI and Musella Foundation Award Grants for ONC201 Trials in Adult and Pediatric Brain Tumors

    Philadelphia, PA (September 10, 2018) – Oncoceutics, Inc. announced the receipt of a Small Business Innovation Research (SBIR) Phase IIB Bridge Award from the National Cancer Institute (NCI).  The NCI SBIR Bridge Award will allow Oncoceutics to expand and accelerate its clinical trials evaluating ONC201 in patients with a specific type of lethal brain cancer

    • AUG 06 2018

    Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors

    Philadelphia, PA (July 31, 2018) – Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology. Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the